Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director · Chief Executive Officer | February 18, 2022 | February 23, 2022 |
| REVVITY, INC.RVTY · Entity 3382 | Director | May 07, 2026 | May 11, 2026 |
| Zai Lab LtdZLAB · Entity 4271 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,261.188 |
Ending reported balance
After 2022-02-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-18 · Exercise / conversion · Acquired 6,191 · Balance 70,007.188 Row 2 · 2022-02-18 · Tax withholding · Disposed 2,746 · Balance 67,261.188 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2024-02-18 | Direct | 39,119 |
Reported balance
After 2022-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-18 · Exercise / conversion · Disposed 6,191 · Balance 39,119 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2024-02-18 | Direct | 30,210 |
Reported balance
After 2022-02-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-18 · Other · Disposed 8,909 · Balance 30,210 F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
REVVITY, INC.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,977 |
Ending reported balance
After 2026-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-07 · Grant · Acquired 1,015 · Balance 12,712 F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Row 2 · 2026-05-07 · Grant · Acquired 1,265 · Balance 13,977 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.
Zai Lab Ltd
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 72,787 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 22,371 · Balance 72,787 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:08 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 22,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003027 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,787 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-216727 · ownership.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,977 Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-216727 · ownership.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,712 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:11 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 10,831 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002220 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,416 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2026, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,338 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-061826 · ownership.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,697 Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-061826 · ownership.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,359 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 28, 2026, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 21,253 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001751 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,585 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2025, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,218 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052069 · ownership.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,285 Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 977 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052069 · ownership.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,067 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 22, 2025, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:06 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 955 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-022714 · ownership.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,090 Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:06 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-022714 · ownership.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,135 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 23, 2024, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 18,332 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007332 · doc4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,332 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. Read SEC document |
| May 06, 2022 Filed May 9, 2022 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 744 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017248 · doc4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,352 Read SEC document |
| May 06, 2022 Filed May 9, 2022 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 610 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017248 · doc4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,608 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 25, 2023, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 8,909 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006280 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,210 Underlying: Common Stock · 8,909 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 6,191 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006280 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,119 Underlying: Common Stock · 6,191 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,746 | $209.79 | $576,083.34 |
DisclosureSEC source: 0001127602-22-006280 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,261.188 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 6,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006280 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,007.188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 8,163 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · derivative · entry 9 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,564 Underlying: Common Stock · 8,163 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 4,395 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · derivative · entry 8 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,727 Underlying: Common Stock · 4,395 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 8,205 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · derivative · entry 7 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,205 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 4,321 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · derivative · entry 6 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,205 Underlying: Common Stock · 4,321 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 4,699 | $214.59 | $1,008,358.41 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 5 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,816.188 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,950 | $214.59 | $418,450.50 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,515.188 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 4,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,465.188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,917 | $214.59 | $411,369.03 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,070.188 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 4,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,987.188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 28,405 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004775 · form4.xml · derivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,405 Underlying: Common Stock · 28,405 shares Expires 2025-02-10 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:45 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 10,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001859 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,666.188 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022. F2 · balance_after: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:17 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 709 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018993 · doc4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,998 Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:17 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018993 · doc4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,289 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 26, 2022, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 45,310 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007011 · form4.xml · derivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,310 Underlying: Common Stock · 45,310 shares Expires 2024-02-18 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 7,221 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · derivative · entry 13 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,122 Underlying: Common Stock · 7,221 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 5,337 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · derivative · entry 12 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,343 Underlying: Common Stock · 5,337 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 7,263 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · derivative · entry 11 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,526 Underlying: Common Stock · 7,263 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 5,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · derivative · entry 10 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,789 Underlying: Common Stock · 5,259 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 6,419 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · derivative · entry 9 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,419 shares Expires 2021-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 5,693 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · derivative · entry 8 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,419 Underlying: Common Stock · 5,693 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,367 | $278.03 | $658,097.01 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · nonDerivative · entry 7 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,969.286 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,333 | $278.03 | $648,643.99 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · nonDerivative · entry 6 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,336.286 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,525 | $278.03 | $702,025.75 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · nonDerivative · entry 5 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,669.286 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 5,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · nonDerivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,194.286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 5,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · nonDerivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,857.286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 5,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,598.286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:03 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 7,248 | $278.03 | $2,015,161.44 |
DisclosureSEC source: 0001127602-21-006281 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,905.286 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 29, 2021. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:41 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 16,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002973 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,153.286 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2018. The shares will vest on February 12, 2021. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 21:57 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 3,100 | $241.31 | $748,046.74 |
DisclosureSEC source: 0001127602-20-030238 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,810.286 F1 · balance_after: Includes 84.965 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2020. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 1,081 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012808 · doc4.xml · nonDerivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,685 Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 244 | $92.20 | $22,496.80 |
DisclosureSEC source: 0000899243-20-012808 · doc4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,604 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2021, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. F2 · price: Restricted stock units were awarded in lieu of the reporting person's first 2020 quarterly cash retainer payment, with the number of restricted stock units determined by dividing the amount of the cash retainer payment by the Black-Scholes value of a restricted stock unit on the date the grant was made. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:05 UTC | REVVITY, INC. PKI · Entity 3382 | GrantCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012808 · doc4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,360 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2021, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.